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Chronic inflammatory skin diseases like psoriasis alter the local skin microbiome
and lead to complications such as persistent infection with opportunistic/pathogenic
bacteria. Disease-associated changes in microbiota may be due to downregulation
of epidermal antimicrobial proteins/peptides, such as antimicrobial protein chemerin.
Here, we show that chemerin and its bioactive derivatives have differential effects on
the viability of different genera of cutaneous bacteria. The lethal effects of chemerin
are enhanced by bacterial-derived ROS-induced chemerin peptide oxidation and
suppressed by stationary phase sigma factor RpoS. Insight into the mechanisms
underlying changes in the composition of cutaneous bacteria during autoreactive skin
disease may provide novel ways to mobilize chemerin and its peptide derivatives for
maximum antimicrobial efficacy.
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INTRODUCTION
To prevent pathologic outcomes, the skin must continuously confront a wide and diverse
array of bacterial challenges. The primary line of defense relies on keratinocytes and their
ability to secrete antimicrobial peptides. Among keratinocyte-derived factors equipped with
antimicrobial potential is chemerin. Chemerin is a secreted multifunctional protein that is
known mainly for its properties to support immune cell infiltration to inflammatory sites
and regulate differentiation of adipocytes (Wittamer et al., 2003; Zabel et al., 2005b; Goralski
et al., 2007). Chemerin is secreted as a functionally inert precursor protein (Chem163S, with
number and capital letter referring to the terminal amino acid position and single amino
acid code). Chem163S can be converted to active isoforms through posttranslational carboxyl-
terminal processing. Proteolytic cleavage at serine 157 in the carboxyl-terminus of Chem163S
results in generation of Chem157S isoform that is effective in triggering chemotaxis of several
types of immune cells (Yamaguchi et al., 2011). This isoform also exhibits much stronger
growth inhibitory potential compared with Chem163S against bacteria (Kulig et al., 2011;
Godlewska et al., 2017). However, in contrast to C-terminal region responsible for chemotactic
potential, antimicrobial activity is mainly associated with a domain localized in the middle of
the chemerin sequence, Val66-Pro85 peptide (p4), which embodies the majority of chemerin’s
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anti-microbial activity (Banas et al., 2013). Therefore, to exhibit
potent antimicrobial activity, holoprotein Chem163S requires
removal of a terminal inhibitory peptide, possibly to enable
structural accessibility of its antimicrobial domain, and/or a
release of its central antimicrobial peptide. Chem157S has been
isolated from human biological specimens, including ascites
and serum (Zabel et al., 2006). Although cutaneous chemerin
isoforms remain to be identified, endogenous chemerin is largely
responsible for the natural antimicrobial activity present in
keratinocyte secretions (Banas et al., 2013), suggesting that
chemerin isoform(s) capable of controlling bacteria growth are
generated in the epidermis. Given that several chemerin receptors
can retain chemerin on the cell surface (Zabel et al., 2014),
structural features/changes in chemerin structure following
binding to these receptors might enable the p4 domain to
interact with bacteria. Since chemerin is highly susceptible to
proteolytic cleavage (Zabel et al., 2014), it is also likely that
p4 can be released from chemerin by endogenous (Wittamer
et al., 2005; Zabel et al., 2005a; Schultz et al., 2013) or bacteria-
derived proteases (Kulig et al., 2007) and act independently
of the rest of chemerin protein. Synthetic p4 is effective in
treating experimental S. aureus skin infections (Godlewska
et al., 2019), suggesting that it could impact the clinical
management of S. aureus and potentially other bacteria-mediated
skin pathologies.
Despite our growing understanding of the local and systemic
role of chemerin in immunity, the function of this protein at body
barriers remains poorly understood. Chemerin is abundantly
expressed by keratinocytes in healthy skin but it is markedly
downregulated in the epidermis of patients suffering from the
autoinflammatory skin disease psoriasis (Albanesi et al., 2009).
Since the overall microbial community (microbiota) of normal
and psoriatic skin can differ substantially (Gao et al., 2008;
Chang et al., 2018), active chemerin derivatives may contribute
to skin pathophysiology by shaping the composition of the
skin microbiota.
Here, we demonstrate differentiating potentials of chemerin
isoforms and p4 in controlling cutaneous bacteria and
identify novel bacteria-mediated mechanisms that influence
the antimicrobial activity of chemerin peptide, which may




The following laboratory or clinical reference strains were used
in the study: Escherichia coli HB101, Escherichia coli DH5α,
and Escherichia coli NiCo21(DE3); Staphylococcus aureus strain
8325-4, Staphylococcus epidermidis DSM 20044, Staphylococcus
hominis DSM 20328, Staphylococcus capitis DSM 20326,
Staphylococcus caprae DSM 20608, Streptococcus mitis DSM
12643, Corynebacterium simulans DSM 44392, Corynebacterium
tuberculostearicum DSM 44922, Cutibacterium acnes DSM
16379. The clinical reference strains were obtained from DSMZ
German Collection of Microorganisms and Cell Cultures GmbH
(Braunschweig). Rhodobacter capsulatus (R. capsulatus) strains
included R. capsulatus pMTS1/MTRbc1 strain overproducing
cytochrome bc1 (WT), the MT-RBC1 knockout strain with a
deletion of the operon coding for cytochrome bc1, G167P strain
with glycine 167 to proline mutation in the cytochrome b protein
of the bc1complex, and 2Ala with alanine insertion mutation in
the iron-sulfur protein subunit of the bc1complex (Borek et al.,
2008, 2015). R. capsulatus strains were kindly donated by Dr. A.
Osyczka (Dept. of Molecular Biophysics, Jagiellonian University,
Kraków, Poland).
Production of Recombinant Human
Chemerin Isoforms
Recombinant human full-length chemerin variant Chem163S
and chemerin variant Chem157S, lacking 6 aa at C-terminus,
were produced in Escherichia coli. DNA fragments corresponding
to the desired chemerin proteins were amplified by PCR and
cloned into the pNIC28-Bsa4 expression vector (Addgene, LGC
Standards, Teddington, United Kingdom) at a site preceded by
the sequence coding for hexahistidine tag, using the overlap-
extension PCR (Bryksin and Matsumura, 2010). Both constructs
lacked the first 20 aa native chemerin signal peptide. The identity
of the created pNIC28-Bsa4-chem157 or pNIC28-Bsa4-chem163
constructs was verified by sequencing (Genomed, Warsaw,
Poland). Recombinant chemerin isoforms were expressed and
purified in E. coli strain NiCo21(DE3) (New England Biolabs,
MA, United States), transformed with the plasmids described
above. Recombinant proteins were purified from the inclusion
bodies of bacteria transformants, using Ni-Sepharose 6 Fast Flow,
followed by Q Sepharose Fast Flow (both from GE Healthcare,
Uppsala, Sweden). The recombinant chemerin variants were
first eluted with 500 mM imidazole, and in the second
purification step with 25–35 mM (Chem163S) or 35–50 mM
(Chem157S) NaCl and dialyzed against PBS. The obtained
proteins were routinely >90% pure as assessed by SDS-PAGE and
Coomassie Blue staining.
Chemerin Peptide 4 (p4)
Peptide p4 was chemically synthesized by ChinaPeptide
(Shanghai, China) at ≥95% purity. Biotin- or FITC-labeled
p4 were synthesized by CASLO (Kongens Lyngby, Denmark)
at ≥95% or ≥98% purity. Biotin was added directly at the
N-terminus of p4. For FITC-labeled p4, C-terminal lysine was
added to p4 and FITC was conjugated to the side chain of this
C-terminal lysine. Both biotin-labeled and FITC-labeled p4
displayed similar antimicrobial activity to unmodified p4.
Antimicrobial Microdilution Assay (MDA)
For antimicrobial experiments all staphylococci and C. acnes
were cultured in brain heart infusion broth (BHI) (Sigma-
Aldrich). S. mitis and C. simulans were cultured in BHI
supplemented with 0.3% yeast extract (Sigma-Aldrich), whereas
C. tuberculostearicum was grown in BHI supplemented with
0.3% yeast extract and 1% Tween 80 (Sigma-Aldrich). Bacteria
were grown under aerobic condition with two exceptions.
C. acnes was grown in BHI in an anaerobic atmosphere using a
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GasPakTM EZ Anaerobe Pouch System (BD), and S. mitis was
grown in a 5% CO2 atmosphere using a GasPakTM EZ CO2
Pouch System (BD). To determine the antimicrobial activity of
chemerin and peptide p4 against skin-associated species, bacteria
in mid-logarithmic phase were diluted to 4 × 105 CFU/ml
with PBS containing a series of 2-fold dilution of p4, chemerin
isoforms Chem157S and Chem163S (5 µM), or PBS (control)
and incubated for 2 h. The number of viable bacteria were
enumerated by colony forming units (CFU) counting. In the
experiments with R. capsulatus strains, bacteria were grown
protected from light in mineral-peptone-yeast extract (MPYE)
at 30◦C. Bacteria in mid-logarithmic phase were diluted to
4 × 105 CFU/ml with PBS containing 1% (v/v) of medium and
preincubated with 2 µM antimycin (Sigma-Aldrich) for 15 min
to promote ROS production by bc1, before adding 2.5 µM p4. The
number of viable bacteria were enumerated by CFU counting.
To determine whether susceptibility to p4 is growth-dependent,
E. coli WT and rpoS mutants were cultured in Luria-Bertani (LB)
medium (Sigma-Aldrich), and when required supplemented with
antibiotics. Bacteria in logarithmic or stationary growth phase
were diluted to 4 × 105 CFU/ml with PBS containing a series of
2-fold dilution of p4 or PBS (control) and incubated for 2 h. The
surviving bacteria were enumerated by CFU counting.
ATP Determination
Total ATP levels were determined using The BacTiter-Glo
viability assay kit R© (Promega), following the manufacturer’s
instructions. In brief, bacteria in mid-logarithmic phase were
diluted to 8 × 106 CFU/ml with PBS containing a series of
2-fold dilution of p4 or PBS (control). After incubation with
p4, BacTiter-Glo reagent was added to each well (1:1 [v:v])
and incubated in darkness for 5 min at room temperature
(RT). The luminescent signal was recorded using Tecan Infinite
M200 Plate Reader.
Fluorometric Measurement of Membrane
Potential
Membrane potential was measured by using a voltage-sensitive
dye DiSC3(5) (Sigma-Aldrich). E. coli or S. epidermidis cultures
were grown in BHI to the mid-logarithmic phase and diluted to
an OD600 of 0.2. 15 mM. EDTA was added to E. coli dilution
to facilitate the uptake of the DiSC3(5). DiSC3(5) was added to
each well to a final concentration of 1 µM followed by 25 µM p4
to monitor the dissipation of membrane potential. Gramicidin
(1 µM) (Sigma-Aldrich) was used as a positive control. The
fluorescence at an excitation wavelength of 615 nm and an
emission wavelength of 665 nm was measured using Tecan
Infinite M200 Plate Reader.
Fluorescence Microscopy
Escherichia coli in logarithmic or stationary phase (1× 108 CFU)
were incubated for indicated time with FITC-labeled p4. Cells
were washed three times with PBS to remove the peptide,
attached to slides by cytospin centrifugation, fixed in 3.7%
paraformaldehyde (Sigma-Aldrich), and counterstained with
1 µg/mL Hoechst dye 33258 (Life Technologies) for 30 min
at RT. Images were captured with a fluorescence microscope
(Eclipse; Nikon) and analyzed using NIS-Elements (Nikon)
Imaging Software AR 5.01.00. Nucleoid lengths were measured
automatically. Stained nucleoids less than 42 µm in length or
obtained from cell duplicates were excluded from data analysis.
Quantification of FITC-p4 labeled cells was done manually using
NIS-Elements software.
DNA Binding Assay
Total genomic DNA from E. coli was isolated using a DNA
extraction kit (Thermo Fisher Scientific), according to the
manufacturer’s instruction. Gel retardation experiments were
performed by mixing 150 ng of the DNA and increasing amounts
of p4 in buffer containing 10 mM Tris–HCl, 1 mM EDTA, pH 8.0.
The mixtures were incubated at RT for 30 min, and subsequently
analyzed by electrophoresis on a 0.8% agarose gel in the TBE
buffer (90 mM Tris-borate, 2 mM EDTA, pH 8.3).
qRT-PCR
The total fraction of RNAs was isolated from the E. coli
HB101 using Total RNA Zol-OutTM (A&A Biotechnology) and
converted to cDNA using NxGen M-MulV reverse transcriptase
(Lucigen) with random hexamers (Promega). Real time PCR
was performed on the C1000 Thermal cycler (CFX96 Real
Time System, Bio-Rad) using SYBR Green I containing
universal PCR master mix (A&A Biotechnology) and primers
specific for 16S rRNA, 5′- TGTSTGCAYGGYTGTCGTCA-
3′, 5′- ACGTCRTCCMCACCTTCCTC-3′; gyrA, 5′- CGAGCG
CGGATATACACCTT-3′, 5′- TCCGGTATCGCCGTAGGTAT-
3′ (Genomed).
Transmission Electron Microscopy (TEM)
5× 108 E. coli, S. epidermidis, or S. aureus cells were treated with
p4 or vehicle (PBS) for 2 h at 37◦C. E. coli cell pellets were fixed
in 2% glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 7.4)
overnight at 4◦C while Staphylococci pellets were washed three
times in PBS for 5 min and fixed overnight in 2.5% glutaraldehyde
in PBS at 4◦C. E. coli was then washed in 0.1M sodium cacodylate
buffer, post-fixed in 1% osmium tetroxide in 0.1M cacodylic
buffer for 1 h at RT, washed again two times in the buffer and
distilled water, and stained “en bloc” with 2% uranyl acetate
aqueous solution for 1 h at RT. S. aureus was washed in PBS
and post-fixed with 1% osmium tetroxide for 2 h at 4◦C. Samples
were embedded in epoxy resin (PolyBed 812; Polyscienses, Inc.,
Warrington, PA, United States) after dehydration in graded
ethanol series (50–100%) and in propylene oxide. Ultrathin
sections (65 nm) were cut using ultramicrotome (Leica EM UC7)
and post-stained with uranyl acetate and lead citrate. Specimens
were observed using a transmission electron microscope (JEOL
JEM2100) operating at an accelerating voltage of 80 kV.
Immunogold Labeling
Escherichia coli bacteria were treated with p4-biotin or unlabeled
p4 as a control. Ultrathin sections of the bacteria on nickel
grids were incubated with 4% sodium metaperiodate for 10 min,
followed by 1% aqueous periodic acid for 10 min, and 1% fish
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skin gelatin (FSG) in PBS for 2 h. Sections were incubated
with primary mouse anti-biotin Abs (clone 3D6.6) in 1% FSG
overnight at 4◦C followed by secondary antibodies (12 nm
Colloidal Gold-Donkey anti-mouse Abs; both from Jackson
ImmunoResearch) for 2 h at RT. Sections were fixed in 1%
glutaraldehyde for 5 min, stained with uranyl acetate, and
examined in TEM.
Scanning Electron Microscopy (SEM)
Preparation of the bacteria samples was conducted in the same
manner as for TEM procedure. In brief, bacteria in mid-
logarithmic phase were incubated with p4 or PBS for 2 h at 37◦C
on coverslips in 12-wells plates. After incubation bacteria were
fixed for 10 min in 2.5% glutaraldehyde in PBS, washed three
times with PBS, and dehydrated in gradient ethanol series (15–
100%). The samples were then transferred to a mixture (1:1, v:v)
of ethanol and acetone, and pure acetone for two times 10 min
each. Dry specimens were then coated with gold. Examination
and photography were carried out with a HITACHI S-4700
scanning electron microscope.
CRISPR/Cas9 Genome Editing
The plasmids, primers, and sgRNA target used to CRISPR/Cas-
induced genetic modifications in E. coli are listed in Table 1.
Gene targeting sequence was cloned into pgRNA-bacteria
plasmid using Q5 R© Site-Directed Mutagenesis Kit (New England
BioLabs). For knockout mutation, electrocompetent E. coli
HB101 was transformed with pCas plasmid and isolates were
selected on LB agar plates containing kanamycin (50 µg/ml)
(BioShop). Bacteria harboring pCas were then grown at 30◦C
in LB medium with kanamycin (50 µg/ml). Arabinose (10 mM
final concentration) (Sigma-Aldrich) was added to the culture
at an OD600 of 0.3 to 0.4 for induction of the recombinase
(λ-Red) expression. When the optical density reached 0.5 to
0.7, cells were harvested, washed three times in ice-cold 10%
glycerol, and mixed with 100 ng of pgRNA-bacteria plasmid and
1 µg of donor DNA (containing stop codon and sequence for
HindIII digestion). Electroporation was done in a pre-chilled
2-mm electroporation cuvette (Sigma-Aldrich) at 2.5 kV and
5 ms. Cells were recovered in LB medium without antibiotics
for 1 h at 30◦C, plated onto LB agar containing kanamycin
(50 µg/ml) and ampicillin (100 µg/ml) (Sigma-Aldrich) and
incubated overnight at 30◦C. Transformants were verified by
colony PCR, HindIII (Thermo Fisher Scientific) digestion, and
DNA sequencing (Genomed). Experiments with silencing rpoS
expression were performed as follows. The chemical competent
E. coli DH5α was transformed with plasmid pdCas9-bacteria
expressing catalytically “dead” dCas9. The positive clones were
selected on LB agar plates containing 25 µg/ml chloramphenicol
(Sigma-Aldrich) and used for additional chemical transformation
with pgRNA-bacteria plasmid. For the knockdown experiments,
bacteria were grown in LB supplemented with antibiotics
overnight at 37◦C. The following day, bacteria were diluted
and incubated in LB with appropriate antibiotics for additional
6 h to OD600 of 0.5–0.8. To obtain KD phenotype LB was
additionally supplemented with 0.1 µM anhydrotetracycline
(aTc) (Cayman Chemical).
RESULTS
Chem157S and p4 Display Differential
Antimicrobial Activity Against Skin
Bacteria
Previous studies have identified specific alterations in the
cutaneous microbiome in lesional psoriatic skin vs. healthy
TABLE 1 | List of plasmids, primers, and sgRNA sequences used in the CRISPR/Cas9 experiments.
Plasmid Purpose Source
pgRNA-bacteria Expression of guide RNA (gRNA) Addgene #44251
pCas Constitutive expression of cas9 and inducible expression of λ-Red Addgene #62225
pdCas9-bacteria aTc-inducible expression of a catalytically inactive bacterial Cas9 (dCas9) Addgene #44249
Primers
CCATAACGGGTTTTAGAGCTAGAAATAGC Insertion of gene targeting sequence in pgRNA-bacteria plasmid This study
CAATCGTGGTCACTAGTATTATACCTAGGAC Insertion of gene targeting sequence in pgRNA-bacteria plasmid This study
GGCGTATCACGAGGCAGAAT Identification of modification of pgRNA-bacteria plasmid This study
CGACTCGGTGCCACTTTTTC Identification of modification of pgRNA-bacteria plasmid This study
GTTGCGTATGTTGAGAAGCGG Amplification of rpoS This study
AACTGTTATCGCAGGGAGCC Amplification of rpoS This study
AACGCCAGCTAAAGC Binding to modified fragment of rpoS This study
AAATCGGCGGAACCA Binding to modified fragment of rpoS This study
Target part of gene (+PAM sequence)




Modification of rpoS This study
TGCGTCTGGTGGTAAAAATTGCCCGCCGTTAAGGC
AAGCTTTAGCTGGCGTTGCTGGACCTTATCGAAGA
Modification of rpoS This study
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skin (Gao et al., 2008; Fahlen et al., 2012). Since chemerin
is substantially reduced in psoriatic (lesional and non-lesional)
epidermis vs. healthy epidermis, we hypothesized that psoriatic
epidermis is preferentially inhabited by bacteria that are sensitive
to chemerin antimicrobial activity. To test this hypothesis, we
selected a diverse set of nine common clinical bacterial isolates
altered in psoriatic skin for chemerin-mediated killing activity.
These include S. aureus, S. hominis, S. epidermidis, S. capitis, S
caprae, Streptococcus mitis (Str. mitis), Corynebacterium simulans
(C. simulans), C. tuberculostearicum, and Propionibacterium
acnes recently renamed Cutibacterium acnes (C. acnes) (Table 2).
Chem157S (5 µM) restricted the growth of all Staphylococcus
spp. and C. simulans, but it was ineffective against Str. mitis
and C. acnes. In contrast, Chem163S had no antimicrobial
activity against most tested strains with exception of S. caprae
(Figure 1). Chemerin peptide p4 and Chem157S shared a similar
pattern of activity against cutaneous microbiota (Figure 1 and
Table 2), but the effects of p4 were overall more robust than
Chem157S based on the complete inhibition of growth of
sensitive bacteria at concentration ≥MIC (Table 2). Specifically,
among the sensitive strains, p4 displayed best efficacy against
C. tuberculostearicum, S. caprae, S. capitis, and S. epidermidis
(MIC = 3.1–6.3 µM) (Table 2). P4 was ineffective against C. acnes
and Str. mitis (Table 2). Therefore, antimicrobial chemerin
TABLE 2 | Antimicrobial activity of peptide p4 against skin bacteria.
Strain MIC [µM] Sensitive/Resistant [100 µM] Strain-level skin changes, healthy individuals vs. donors with psoriasis
S. aureus 8325-4 12.5–25 S ↑ Gao et al., 2008; Chang et al., 2018
S. hominis DSM 20328 12.5–25 S ↑ Gao et al., 2008
S. epidermidis DSM 20044 6.3 S ↑ Gao et al., 2008
S. capitis DSM 20326 3.1–6.3 S ↑ Gao et al., 2008
S. caprae DSM 20608 3.1 S ↓∼ Gao et al., 2008
Str. mitis DSM 12643 ≥100 R ↓ Gao et al., 2008
C. simulans DSM 44392 6.3 S ↑ Gao et al., 2008
C. tuberculostearicum DSM 44922 3.1 S ↑ Gao et al., 2008
C. acnes DSM 16379 >100 R ↓ Gao et al., 2008; Chang et al., 2018
Selected cutaneous bacteria previously shown to be qualitatively altered in psoriatic vs. healthy skin were incubated with chemerin p4. The MIC was defined as the lowest
concentration of p4 showing no visible growth (100% of killing). Strains were defined as sensitive (S) or resistant (R) if they were or were not completely killed by 100 µM
p4, respectively, in all experiments, n = 3.
FIGURE 1 | Chemerin controls growth of cutaneous bacteria. Bacteria were incubated with chemerin isoforms Chem157S, Chem163S (5 µM), or PBS (control) for
2 h. Cell viability in CFU/ml, shown as the percentage of control cells, was analyzed by MDA assay. Results are expressed as the mean ± SD of at least two
independent experiments, performed with technical triplicates. ***p < 0.001, **p < 0.01, *p < 0.05 by one-way ANOVA with post hoc: Tukey’s multiple comparisons
test.
Frontiers in Microbiology | www.frontiersin.org 5 August 2020 | Volume 11 | Article 1819
fmicb-11-01819 August 7, 2020 Time: 19:3 # 6
Godlewska et al. Antimicrobial Chemerin and Chemerin Peptide p4
derivatives exhibit selectivity against common and psoriasis-
relevant cutaneous microbes.
P4 Suppresses Bacteria Growth by
Directly Targeting Envelope-Dependent
and Independent Pathways
To better understand strain-dependent differences in p4 efficacy,
we extended our analysis into mechanisms by which p4 controls
bacteria growth. We previously showed that peptide p4 rapidly
destabilized membrane integrity in p4-sensitive E. coli strains
(MIC = 6.3–12.5 µM). However, we noted that p4 localized
to multiple bacteria cell compartments 10 min after treatment,
including the cell wall and nucleoid (Godlewska et al., 2019)
and Figure 2A, suggesting that p4 affects bacteria viability
by directly interfering with several key pathways. Combined
scanning and transmission electron microscopy (SEM and TEM,
respectively), demonstrated massive loss of cell surface structures
and/or peeled cell envelope in E. coli and/or S. epidermidis
(Figure 2B), indicating ultrastructural disruption of bacterial
membranes and peptidoglycan layers in both Gram+ and Gram-
strains. Treatment of E. coli with p4 also resulted in a tendency
FIGURE 2 | Chemerin peptide p4 localizes in different bacterial cell compartments and disrupts the cell envelope. (A) Localization of p4 is shown by immunogold
labeling, followed by TEM. E. coli was incubated with 100 µM biotin-p4 (upper panel) or p4 as a control (lower panel) for 10 min, fixed, and stained with mouse
anti-biotin Abs, followed by anti-mouse Abs conjugated to gold particles. Arrowheads and asterisks indicate interaction of p4 with cell envelope and nucleoid,
respectively. (B) The indicated bacteria strains were incubated with 100 µM p4 or vehicle control (PBS) for 2 h, followed by SEM (upper and middle rows) or TEM
(lower row). TEM and SEM images are from one experiment and are representative of at least three experiments. Scale bar = 300 nm (A), 1 µm (B SEM) or 100 nm
(B, TEM). (C) E. coli and S. epidermidis were incubated with 25 µM p4, 1 µM gramicidin as a positive control, or vehicle control (PBS) for 10 min followed by
measurement of membrane potential by fluorimetry. (D) E. coli and S. epidermidis were incubated with p4, or vehicle control (PBS) for 10 min followed by
measurement of total ATP levels. Membrane potential (C) or ATP levels (D) are shown as the percentage of a vehicle-treated cells. Results are expressed as the
mean ± SD of at least three independent experiments, performed in duplicates. ***p < 0.001, **p < 0.01, *p < 0.05, ns = non-significant by one-way ANOVA with
post hoc: Tukey’s multiple comparisons test.
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for, and significant depolarization of, membrane potential in
E. coli and S. epidermidis, respectively (Figure 2C), as well as
accompanying loss of ATP levels (Figure 2D). Together, these
data indicate that p4 affects bacteria growth by targeting bacteria
shield components.
P4 also induced condensation of bacteria chromosome in
E. coli and Staphylococci (Figures 2A, 3A). Given the rapid
localization of p4 on nucleoid (Figure 2A), these data suggested
that p4 binding to DNA may interfere with the chromosome
structure. In E. coli, nucleoid condensation occurs naturally
during the stationary phase of growth. Fluorescence microscopy
revealed that, in common with E. coli in the stationary phase,
bacteria incubated in the presence of 10 µM p4 but not vehicle
control for 30 min significantly reduced the nucleoid length
in the log phase. This was visualized as a change of shape
of nucleoids from rod-like, relaxed form in the log phase
of growth to more compact, lobular forms in the stationary
phase, and in the log phase in response to p4 (Figure 3B). In
contrast, condensation of bacteria nucleoids, already robust in
stationary phase without any treatment, was much less dependent
on p4. The qualitative data were corroborated by quantitative
length measurement of Hoechst-labeled bacterial chromosomes
by fluorescence microscopy (Figure 3C). To explore the direct
DNA-interacting ability of p4, we performed gel retardation
analysis to assess the electrophoretic mobility of DNA. Increasing
concentrations of p4 retarded the migration of bacterial DNA
(Figure 3D). Maximal inhibition was noticed when DNA was
exposed to p4 at concentrations above the MIC (12.5–100 µM);
however, a lower concentration of p4 (that corresponds to
1×MIC) was sufficient for partial retardation of DNA migration.
The inhibitory effect was negligible for sublethal concentrations
of p4 (Figure 3D). To determine whether the interaction
between p4 and DNA can influence overall bacterial fitness, we
determined transcription levels of two house-keeping genes: 16S
rRNA and gyrA. Expression of these genes in response to p4 was
not significantly altered in either log or stationary phase of growth
by qPCR (Figure 3E). These data suggest that p4 is not able
to inhibit transcription of constitutively expressed genes, despite
interacting with DNA and impacting nucleoid condensation.
Bacteria Modulate Sensitivity to p4 by
Influencing p4 Oxidation and Cell
Surface Localization
Since P4 is not uniformly bactericidal, it is possible that bacteria
may employ countermeasures to ameliorate the damaging effects
FIGURE 3 | Bacteria treatment with p4 results in robust nucleoid condensation in logarithmic phase of growth. (A) The indicated bacteria strains were incubated
with 100 µM p4 or vehicle control for 2 h, followed by TEM. (B) E. coli in the indicated phase of growth was incubated with 10 µM FITC-labeled p4 or vehicle control
for 30 min, stained with Hoechst to visualize DNA, and analyzed by fluorescence microscopy. FITC-p4 positive cells are shown as the percentage of total cells
(Mean ± SD). (C) Length of nucleoids were measured in p4 or vehicle-treated E. coli images using NIS-Elements Imaging Software, n = 3. In each experiment, at
least 2 or 3 different high-power fields were analyzed. Results are expressed as the mean ± SD. ***p < 0.001, *p < 0.05 by Kruskal-Wallis one-way ANOVA with
Post hoc Dunn’s test. (D) E. coli-derived DNA was incubated with the indicated concentration of p4 and analyzed by gel-retardation assay, n = 3. (E) Expression of
the indicated house-keeping genes was analyzed by qPCR in E. coli grown in the logarithmic or stationary phase and treated with 5 µM p4 or vehicle (PBS) for
30 min, n = 3. Expression is shown as the percentage of vehicle-treated cells. Images in panel (A) are from one experiment and are representative of at least three
experiments. Scale bar = 500 nm for E. coli and 200 nm for S. aureus (A) and 2 µm (B).
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of p4. We showed that an oxidative environment can strongly
augment p4 antimicrobial activity by supporting the formation
of disulfide bonds leading to potent antimicrobial p4 dimers
compared to barely active p4 monomers (Godlewska et al., 2019).
To test whether bacteria themselves can modulate antimicrobial
activity of p4 by oxidizing the peptide, we employed highly
p4-sensitive Gram negative bacteria, Rhodobacterium capsulatus
(R. capsulatus) (MIC = 5 µM) (Godlewska et al., 2019). In
common with E. coli and staphyloccoci, p4 triggered robust
morphological cell alterations, including cell layers distortion and
condensation of nuclear material in R. capsulatus (Figure 4A).
The p4-mediated effect on R. capsulatus also manifested in a
rapid drop in ATP levels above MIC (Figure 4B). Changes in
cytoplasmic ATP levels in response to p4 were at least partly
dependent on electron transport chain (ETC), since R. capsulatus
deficient in one of its key ETC enzymes, cytochrome bc1 (mutant
MT-RBC1 KO), was less sensitive to sublethal and lethal p4 levels
(Figure 4B). These data further support our previous findings,
that p4 restricts the growth of R. capsulatus in association
with cytochrome bc1 activity, which has an ability to facilitate
the formation of antimicrobial p4 dimers via p4 oxidation
(Godlewska et al., 2019).
To mimic the conditions under which ETC may enhance
p4 activity, we forced the bc1-dependent superoxide generation
by treatment of bacteria with antimycin (Borek et al., 2008,
2015). We reasoned that the sublethal antimycin administration
in strains capable of producing reactive oxygen species (ROS)
when treated with antimycin, would oxidize the peptide and
boost p4 effect against R. capsulatus. Indeed, WT R. capsulatus
andR. capsulatusG167P mutant with enhanced ability to produce
superoxide in response to antimycin (Borek et al., 2015) were
significantly more sensitive to p4 in the presence of antimycin.
In contrast, there was no antimycin-dependent difference in
antimicrobial p4 activity in two mutated R. capsulatus strains,
MT-RBC1 KO and 2Ala (Borek et al., 2008, 2015), with
markedly diminished ability to produce antimycin-dependent
ROS (Figure 4C). Together, these data suggest that bacteria have
the endogenous ability to calibrate the activation status of p4,
for example, by modulating their oxidative potential by ROS
production at the cell membrane in the vicinity of p4.
Bacteria entering the stationary phase of growth modify their
morphology, metabolic and transcriptional profile for protection
against the harsh environment. These modifications include
increasing resistance to antimicrobial factors (Jaishankar and
Srivastava, 2017; Agrawal et al., 2019). Our observation that
bacteria exposed to p4 in the logarithmic phase of growth
condense their chromosomes in a similar way as untreated
bacteria in the stationary phase (Figure 3) prompted us to
ask whether p4 might induce the development of bacterial
resistance conferred by the “stationary phase phenotype.” The
susceptibility of E. coli to p4 in the logarithmic phase of
growth was significantly higher than in cells in the stationary
phase (Figure 5A). The most notable difference between E. coli
treated with p4 in the log and stationary phase was observed
at sublethal p4 concentrations (1.6 and 3.1 µM). However,
even 100 µM p4 (the highest tested level), in spite of its
strong bactericidal effect, did not completely kill E. coli in the
stationary phase, since 7.4 ± 1.2% (mean ± SD) survived the p4
treatment (Figure 5A).
One of the main factors involved in protection of bacteria
during stress conditions is transcriptional factor σS (RpoS)
(Jaishankar and Srivastava, 2017). We next examined whether
FIGURE 4 | Bacteria capable of producing high level of ETC-dependent ROS are more sensitive to p4. (A) R. capsulatus was incubated with 100 µM p4 or vehicle
(control) for 1 h followed by TEM. Scale bar = 200 nm. (B) R. capsulats (WT) or R. capsulatus deficient with cytochrome bc1 activity (MT-RBC1 KO) was incubated
with the indicated concentration of p4 or vehicle control (PBS) for 30 min followed by measurement of total ATP levels. ATP levels are shown as the percentage of a
vehicle-treated cells. Results are expressed as the mean ± SD of at least three independent experiments, performed in duplicates. ***p < 0.001, *p < 0.05 by
one-way ANOVA with post hoc: Tukey’s multiple comparisons test. (C) The indicated strains of R. capsulatus were incubated with 2 µM of antimycin for 15 min
followed by treatment with 2.5 µM of p4 or vehicle control for 2 h. n = 3. Results are expressed as the mean ± SD. ***p < 0.001, ns = non-significant by one-way
ANOVA with post hoc: Tukey’s multiple comparisons test.
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FIGURE 5 | Bacteria resistance to p4 depends on the phase of growth and involves RpoS-mediated control of p4 interaction with the cell surface. (A) E. coli in the
logarithmic or stationary phase of growth was treated with the indicated concentration of p4, or vehicle control for 2 h. Cell viability in CFU/ml, shown as the
percentage of control cells, was analyzed by MDA assay. n = 3, mean ± SD. (B) E. coli (WT) or E. coli deficient with rpoS gene (rpoS KO) was incubated in the
stationary phase of growth with the indicated concentration of p4 or vehicle control for 2 h followed by MDA assay. n = 3, mean ± SD. (C) WT and rpoS KO E. coli
strains were incubated in the logarithmic phase of growth with the indicated concentration of p4 or vehicle control for 2 h followed by MDA assay. n = 3, mean ± SD.
(D) WT E. coli (upper panel) or E. coli with rpoS gene controlled by aTc (rpoS KD) (lower panel) were treated with 0.1 µM aTC for 6 h to silence rpoS expression. The
bacteria were then treated with the indicated concentration of p4 followed by MDA assay. n = 3, mean ± SD. (E) The indicated E. coli strains were treated with
0.1 µM aTc for 6 h followed by incubation with 20 µM p4 or vehicle control for 10 min. The bacteria were stained with Hoechst to visualize DNA and analyzed by
fluorescence microscopy. Scale bar = 2 µm. FITC-p4 positive cells are shown as the percentage of total cells (Mean ± SD). ***p < 0.001, **p < 0.01, *p < 0.05 by
one-way ANOVA with post hoc: Tukey’s multiple comparisons test.
RpoS played a role in adaptability of bacteria to the p4-mediated
threat. We used CRISPR/Cas to generate E. coli genetically
deficient in RpoS (rpoS KO). During stationary phase, RpoSKO
were significantly more susceptible to p4 than WT E. coli
(Figure 5B). In contrast, rpoS KO bacteria maintained the
p4 sensitivity of the WT strain in the logarithmic phase of
growth (Figure 5C), in agreement with RpoS function confined
to the stationary phase. Similar results were obtained using
an inducible system for silencing rpoS gene (rpoS knockdown,
KD). A decreased tolerance to antimicrobial effect of p4
was correlated with the activity of rpoS gene (controlled by
aTc) in rpoS knockdown E. coli stain but not in the WT
strain (Figure 5D).
Escherichia coli in the stationary phase bound less FITC-
labeled p4 than E. coli in the logarithmic phase (Figure 3B).
These data suggested that RpoS renders bacteria less susceptible
to p4 by promoting the spatial segregation of the peptide and
bacteria at the cell surface. To test this possibility, we examined
binding of p4 to E. coli with the silenced rpoS. Compared to
the WT E. coli, the rpoS knockdown mutant displayed markedly
higher potential for binding of FITC-labeled p4 to the cell surface
(Figure 5E). We conclude that the phenotypic resistance to p4
involves RpoS-dependent limiting of p4 association with the
bacterial surface.
DISCUSSION
Chronic inflammatory skin diseases, including psoriasis, are
associated with microbial cutaneous community changes that
can negatively impact skin health. Although no single microbial
biomarker indicative of psoriasis has been found, several
microorganisms were linked to disease exacerbation, including
chemerin-sensitive S. aureus (Tomi et al., 2005).
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The skin defense system engages many components,
including microbiota- and epidermis-derived antimicrobial
factors (Kwiecien et al., 2019), suggesting that expression-level
variations of these factors might play a pathogenic role in altering
the cutaneous microbiome. However, in contrast to antimicrobial
factors of microbial origin that can be expected to mainly affect
the growth of other strains that compete for the same cutaneous
niche, AMPs that are highly expressed in the epidermis such as
chemerin may play a dominant role in restricting skin associated
microbiota. Here we demonstrate the selectivity of antimicrobial
chemerin derivatives against psoriasis-relevant cutaneous
bacteria strains. Among nine tested strains, seven followed
the predicted pattern of sensitivity to chemerin peptides in
correlation with a diverse skin distribution in healthy (chemerin
rich) and psoriasis (chemerin poor) epidermis. Among the
sensitive chemerin strains were C. tuberculostearicum, S. capitis,
C. simulans, S. epidermidis, S. hominis, and S. aureus. These
strains were also reported to be present in higher quantities
in non-lesional skin of psoriasis patients compared to healthy
skin (Gao et al., 2008; Table 2), when epidermal chemerin
levels may start to decline. In contrast, Chem157S and p4
resistant-Str. mitis, which could be expected to be largely spared
by chemerin peptides in epidermis, was on average unchanged
or less abundant in skin of psoriasis individuals (Gao et al., 2008;
Table 2). However, association with chemerin levels was not
observed for chemerin-resistant C. acnes, which was markedly
underrepresented in psoriasis skin, as well as chemerin-sensitive
S. caprae, which remained unchanged in psoriatic vs. healthy skin
(Gao et al., 2008; Chang et al., 2018). The major determinants of
skin inhabitance with these bacteria likely involve other factors.
For example, C. acnes colonizes lipid-rich sebaceous skin areas.
Since psoriatic skin is rather desiccated, skin dryness may be key
factor in limiting C. acnes abundance in psoriatic skin. Chemerin
exhibits antimicrobial potential against pathogenic microbes,
such as S. aureus, as well as more benign skin strains such as
S. epidermidis. Together these data suggest that chemerin does
not selectively spare less harmful bacteria, but rather acts to
restrict overgrowth of a variety of prevalent cutaneous genera,
species, and strains. In the absence of the protective role of
chemerin as an antimicrobial factor in epidermis, chemerin-
controlled bacterial species might have a growth advantage in the
skin undergoing pathological alterations, and thereby contribute
to disease exacerbation.
The prophylactic potential of p4 against skin infection with
a variety of microorganisms, including MRSA infection, and the
therapeutic efficacy of p4 in treating experimental S. aureus skin
infections [(Godlewska et al., 2019) and Table 2] could form
the basis of potential new drugs for the prevention/treatment
of skin infections, independent of the endogenous abundance
of p4 in vivo. Here, we show that p4 is likely to target multiple
bacterial components, including the cell wall, cell membrane,
and chromosome. Although targeting several independent
components can be expected to limit the ability of bacteria to
develop resistance to p4, our data suggests that bacteria can
engage two discrete mechanisms to protect against p4 lethality.
First, ETC-dependent ROS formation augments antimicrobial
potency of p4 (Figure 4). Therefore, bacteria restricted in their
ability to produce ROS at the cell membrane may, at least to
some degree, be protected against the comparatively more lethal
p4 dimers. Second, blocking accessibility of p4 to the bacterial
surface and limiting p4 interactions with the cell membrane
and intracellular targets, such as DNA, might account for better
bacterial tolerance to p4. In accordance with these proposed
mechanisms, bacteria in the stationary phase of growth that
become more resistant to p4 are known to: (i) cope with
oxidative stress, for example, by encoding enzymes that remove
ROS, and (ii) maintain membrane integrity, for example, by
introducing changes to membrane lipid composition (Mitchell
et al., 2017; Guo et al., 2019). Protective mechanisms available
in the stationary phase of growth often activate RpoS-dependent
pathways that both strengthen cell wall permeability barrier and
activate efflux pumps (Kobayashi et al., 2006; Guo et al., 2019).
These findings provide corroborating support for the possible
RpoS-mediated bacterial defensive strategy in response to the p4
threat. Given that rpoS-silenced E. coli diminish p4 integration
to the cell surface layers (Figure 5), bacteria may benefit by
modifying their membrane properties in such a way to prevent p4
cell surface binding. Alternatively, resistance to p4 may involve
alterations of p4 activity in the bacteria microenvironment,
before or concurrent with p4 interactions with bacteria wall
components. This could be a consequence of a release of ions
and other modulating factors to the bacteria environment by
RpoS-dependent efflux pumps.
We have thus characterized differential bactericidal activities
of endogenous active chemerin (Chem157S) and p4 peptide
against common types of cutaneous bacteria known to be
altered in psoriasis. We have also discovered bacteria-mediated
mechanisms that regulate the antimicrobial activity of chemerin.
Given the potential clinical utility of chemerin and p4 in treating
skin infections, insight into how skin bacteria can counteract p4
may prove useful in designing chemerin-based biologics geared
to establish or restore a favorable cutaneous microbiome.
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